Drug · Small Molecule

Bortezomib

CI-DRUG-00000113Explore in graph →NCIt C1851 CHEMBL325041 CIViC Approved

Regulatory

Approvals (51)

Each record names the authority, jurisdiction, indication text and status. A drug approved in one jurisdiction for one indication is not 'approved' in general.

health-canada-dpdRegulatory50 approval records from 3 sources (hover a row badge for its dataset) · authority, jurisdiction and indication text as published.

Jurisdiction · authority	Cancer	Indication	Status	Approval date	Source
CA Health Canada	—	Marketed in Canada as BORTEZOMIB INJECTION (DIN 02550075) under ATC L01XG01 BORTEZOMIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Jul 21, 2025	health-canada-dpd
CA Health Canada	—	Marketed in Canada as BORTEZOMIB FOR INJECTION (DIN 02485257) under ATC L01XG01 BORTEZOMIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Mar 28, 2023	health-canada-dpd
CA Health Canada	—	Marketed in Canada as TARO-BORTEZOMIB (DIN 02511932) under ATC L01XG01 BORTEZOMIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Jul 18, 2022

Health Canada records are DIN-level: one row per marketed product (brand, strength, form). The Drug Product Database does not publish indications, so no cancer is stated for these rows, and a cancelled or dormant DIN is the status of that one product — not a withdrawal of the molecule.

Data updated 18 hours agoSource updated unknown

Derived

Development pipeline

Most advanced stage across all cancers, then per top-level cancer reached through trial conditions or approval indications. Approval in any ingested jurisdiction outranks trial phase; counts are interventional studies.

Scope	Stage	Max phase	Active	Recruiting	Phase 3	Trials	Approvals	Jurisdictions	First approval	First trial
All cancers	Approved	Phase 4	128	52	104	699	51	CA, EU, US	May 13, 2003	1999-07
Non-Hodgkin Lymphoma	Approved	Phase 4	100	36	93	457	8	US	May 13, 2003	Feb 8, 2001
Multiple Myeloma	Approved	Phase 4	87	30	87	353	4	US	May 13, 2003	Feb 8, 2001
Leukemia	Phase4	Phase 4	15	10	5	78	0	—

Curated evidence

Clinical evidence (3)

CIViC items in which this therapy appears, grouped by cancer context, then molecular profile. 50 items per page.

civicCuratedShowing 1–3 of 3 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
GATA2 EXPRESSION1
Bortezomib + Fasudil

Clinical trials

Trials with this intervention (722)

Most recently updated first, 50 per page.

clinicaltrialsPublishedShowing 1–50 of 722 studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT00092222	Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity	active not recruiting	Phase 2	75	National Cancer Institute (NCI)NIH	1	Sep 28, 2026	clinicaltrials
NCT04181827	A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma

Molecule

Record

Kind: Small Molecule
Mechanism: 26S proteasome inhibitor
Targets: 38 genes
UNII: 69G8BD63PP
Aliases: [(1R)-3-Methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(pyrazinylcarbonyl)amino]propyl]amino]butyl]boronic Acid, ACT BORTEZOMIB, Bortezomib, Bortezomib Accord, BORTEZOMIB FOR INJECTION SDZ, Bortezomib Fresenius Kabi, Bortezomib Hospira, Bortezomib hydrate, Bortezomib Mannitol Boronic Ester, Bortezomib Sun, Boruzu, BORUZU, LDP 341, LDP-341, LDP341, MLN 341, MLN341, NSC-681239, PMS-BORTEZOMIB, PS 341, PS-341, PS341, TARO-BORTEZOMIB, Velcade, VELCADE

Data updated 21 hours agoSource updated unknown

Identifiers

Codes (57)

Upstream identifiers kept as first-class codes; each links to its registry where a stable public URL exists.

System	Code	Label
ATC (WHO)	L01XG01	BORTEZOMIB
ATC (WHO)	L01XX32